Pharmaniaga Berhad | Financial Information

Financial Year Ended 31 December	2026	2025	2024	2023	2022
	3 months Actual (Unaudited)	12 months Actual (Audited)	12 months Actual (Audited)	12 months Actual (Audited)	12 months Actual (Restated)
Presented in RM'000
Continuing Operations

Revenue	1,178,524	3,927,753	3,759,479	3,404,481	3,480,935
Cost of sales	(1,050,000)	(3,518,597)	(3,218,985)	(3,096,660)	(3,690,523)
Gross profit	128,524	409,156	540,494	307,821	(209,588)
Other income	92	778	2,971	2,649	3,118
Administrative expenses	(73,507)	(279,511)	(279,568)	(328,267)	(314,716)
Impairment of intangible assets	-	-	-	-	(50,274)
Finance costs	(10,082)	(61,345)	(71,969)	(61,843)	(40,038)
Interest income	1,383	5,659	2,252	1,477	910
(Loss)/Profit before zakat and taxation	46,410	74,737	194,180	(78,163)	(610,588)
Zakat	(2,500)	(1,000)	-	-	(209)
Taxation	(11,720)	(23,053)	(60,386)	(581)	(16,857)
Net (loss)/profit for the financial year	32,190	50,684	133,794	(78,744)	(627,654)

Other comprehensive income/(loss), net of tax:
Items that may be subsequently reclassified to profit or loss
Foreign currency translation differences for foreign operations	(1,841)	(9,181)	(5,906)	3,559	(3,951)
Recognition of actuarial gain/(loss)	-	(34)	238	103	(402)
Item that will not be reclassified to profir or loss
Gain on revaluation of land and buildings	-	426	264	103,654	-
Total comprehensive income/(loss), net of tax for the financial period/year	30,349	41,895	128,390	28,572	(632,007)

Profit attributable to:
Owners of the parent	31,471	48,510	131,822	(80,160)	(629,921)
Non-controlling interests	719	2,174	1,972	1,416	2,267
	32,190	50,684	133,794	(78,744)	(627,654)

Total comprehensive income/(loss) attributable to:
Owners of the parent	30,151	42,361	127,791	24,771	(633,513)
Non-controlling interests	198	(466)	599	3,801	1,506
	30,349	41,895	128,390	28,572	(632,007)

Earnings per share (sen):
Basic	0.48	1.34	9.15	(5.86)	(48.09)
Diluted	0.48	1.34	9.15	(5.86)	(48.09)